|
|
Registros recuperados : 5 | |
1. | | FINKLER, C. L. L.; LIRA NETO, A. de C.; CASTELLETTI, C. H. M.; MARANHÃO, L. M. de A. C. Produção de biolarvicidas à base de Bacillus sphaericus e Bacillus thuringiensis var. israelensis para o controle de insetos. FIGUEIREDO, M. do V. B.; BURITY, H. A.; OLIVEIRA, J. de P.; SANTOS, C. E. de R. e S.; STAMFORD, N. P. (Ed.). Biotecnologia aplicada à agricultura: textos de apoio e protocolos experimentais. Brasília, DF: Embrapa Informação Tecnológica; Recife: Instituto Agronômico de Pernambuco, 2010. p. 609-624. Biblioteca(s): Embrapa Agricultura Digital. |
| |
3. | | ANDRADE, P. P. de; ARAGAO, F. J. L.; COLLI, W.; DELLAGOSTIN, O. A.; FINARDI-FILHO, F.; HIRATA, M. H.; LIRA-NETO, A. de C.; MELO, M. A. de; NEPOMUCENO, A. L.; NOBREGA, F. G. da; SOUSA, G. D. de; VALICENTE, F. H.; ZANETTINI, M. H. B. Use of transgenic Aedes aegypti in Brazil: risk perception and assessment. Bulletin of the World Health Organization, Geneva, v. 94, p. 766-771, Oct. 2016. Biblioteca(s): Embrapa Milho e Sorgo; Embrapa Recursos Genéticos e Biotecnologia. |
| |
4. | | FIGUEIREDO, M. do V. B.; GOMES, E. W. F.; ROSA, R. C. T. da; MESSIAS A. S.; OLIVEIRA, J. de P.; SILVA, D. M. P. da; SOUZA, A. R. de; ASSIS, T. C. de; CAVALCANTI V. A. L. B.; GURGEL, L. M. S.; LEMOS, M. C.; ASSUNÇÃO, M. dos S.; PEREIRA, R. de C. A.; BOCAGE NETA, A. L. du; CANUTO, V. T. B.; MARANHÃO, L. M. de A. C.; LIRA NETO, A. de C.; CASTELLETTI, C. H. M. (ed.). Manual de práticas laboratoriais: um guia para pesquisa. Recife: IPA, 2013. 398 p. il. Biblioteca(s): Embrapa Florestas; Embrapa Semiárido; Embrapa Uva e Vinho. |
| |
5. | | FIGUEIREDO, M. do V. B.; GOMES, E. W. F.; ROSA, R. C. T. da; MESSIAS A. S.; OLIVEIRA, J. de P.; SILVA, D. M. P. da; SOUZA, A. R. de; ASSIS, T. C. de; CAVALCANTI V. A. L. B.; GURGEL, L. M. S.; LEMOS, M. C.; ASSUNÇÃO, M. dos S.; PEREIRA, R. de C. A.; BOCAGE NETA, A. L. du; CANUTO, V. T. B.; MARANHÃO, L. M. de A. C.; LIRA NETO, A. de C.; CASTELLETTI, C. H. M. (ed.). Manual de práticas laboratoriais: um guia para pesquisa. Recife, PE: IPA, 2013. 398 p. il. Biblioteca(s): Embrapa Solos / UEP-Recife. |
| |
Registros recuperados : 5 | |
|
|
Registro Completo
Biblioteca(s): |
Embrapa Milho e Sorgo; Embrapa Recursos Genéticos e Biotecnologia. |
Data corrente: |
03/10/2016 |
Data da última atualização: |
14/06/2024 |
Tipo da produção científica: |
Artigo em Periódico Indexado |
Circulação/Nível: |
A - 1 |
Autoria: |
ANDRADE, P. P. de; ARAGAO, F. J. L.; COLLI, W.; DELLAGOSTIN, O. A.; FINARDI-FILHO, F.; HIRATA, M. H.; LIRA-NETO, A. de C.; MELO, M. A. de; NEPOMUCENO, A. L.; NOBREGA, F. G. da; SOUSA, G. D. de; VALICENTE, F. H.; ZANETTINI, M. H. B. |
Afiliação: |
Paulo Paes de Andrade, Universidade Federal de Pernambuco; FRANCISCO JOSE LIMA ARAGAO, Cenargen; Walter Colli, Universidade de São Paulo; Odir Antônio Dellagostin, Universidade Federal de Pelotas; Flávio Finardi-Filho, Universidade de São Paulo; Mario Hiroyuki Hirata, Universidade de São Paulo; Amaro de Castro Lira-Neto, Instituto Agronômico de Pernambuco; Marcia Almeida de Melo, Universidade Federal de Campina Grande; ALEXANDRE LIMA NEPOMUCENO, CNPSO; Francisco Gorgônio da Nóbrega, Universidade de São Paulo; Gutemberg Delfino de Sousa, Faculdade Anhanguera; FERNANDO HERCOS VALICENTE, CNPMS; Maria Helena Bodanese Zanettini, Universidade Federal do Rio Grande do Sul. |
Título: |
Use of transgenic Aedes aegypti in Brazil: risk perception and assessment. |
Ano de publicação: |
2016 |
Fonte/Imprenta: |
Bulletin of the World Health Organization, Geneva, v. 94, p. 766-771, Oct. 2016. |
DOI: |
10.2471/BLT.16.173377 |
Idioma: |
Inglês |
Conteúdo: |
The OX513A strain of Aedes aegypti, which was developed by the British company Oxitec, expresses a self-limiting transgene that prevents larvae from developing to adulthood. In April 2014, the Brazilian National Technical Commission on Biosafety completed a risk assessment of OX513A and concluded that the strain did not present new biological risks to humans or the environment and could be released in Brazil. At that point, Brazil became the first country to approve the unconstrained release of a genetically modified mosquito. During the assessment, the commission produced a comprehensive list of ? and systematically analysed ? the perceived hazards. Such hazards included the potential survival to adulthood of immature stages carrying the transgene ? should the transgene fail to be expressed or be turned off by exposure to sufficient environmental tetracycline. Other perceived hazards included the potential allergenicity and/or toxicity of the proteins expressed by the gene, the potential for gene flow or increased transmission of human pathogens and the occupation of vacant breeding sites by other vector species. The Zika epidemic both elevated the perceived importance of Ae. aegypti as a vector ? among policy-makers and regulators as well as the general public ? and increased concerns over the release of males of the OX513A strain. We have therefore reassessed the potential hazards. We found that release of the transgenic mosquitoes would still be both safe and of great potential value in the control of diseases spread by Ae. aegypti, such as the chikungunya, dengue and Zika virus disease. MenosThe OX513A strain of Aedes aegypti, which was developed by the British company Oxitec, expresses a self-limiting transgene that prevents larvae from developing to adulthood. In April 2014, the Brazilian National Technical Commission on Biosafety completed a risk assessment of OX513A and concluded that the strain did not present new biological risks to humans or the environment and could be released in Brazil. At that point, Brazil became the first country to approve the unconstrained release of a genetically modified mosquito. During the assessment, the commission produced a comprehensive list of ? and systematically analysed ? the perceived hazards. Such hazards included the potential survival to adulthood of immature stages carrying the transgene ? should the transgene fail to be expressed or be turned off by exposure to sufficient environmental tetracycline. Other perceived hazards included the potential allergenicity and/or toxicity of the proteins expressed by the gene, the potential for gene flow or increased transmission of human pathogens and the occupation of vacant breeding sites by other vector species. The Zika epidemic both elevated the perceived importance of Ae. aegypti as a vector ? among policy-makers and regulators as well as the general public ? and increased concerns over the release of males of the OX513A strain. We have therefore reassessed the potential hazards. We found that release of the transgenic mosquitoes would still be both safe and of great po... Mostrar Tudo |
Palavras-Chave: |
Aedes transgênico; Chikungunya; Método de controle; Mosquito geneticamente modificado. |
Thesagro: |
Doença; Mosquito; Tetraciclina. |
Thesaurus NAL: |
Aedes aegypti; Dengue; Transgenes; Zika virus. |
Categoria do assunto: |
H Saúde e Patologia |
URL: |
https://ainfo.cnptia.embrapa.br/digital/bitstream/item/180103/1/BLT.16.173377.pdf
|
Marc: |
LEADER 02794naa a2200409 a 4500 001 2055427 005 2024-06-14 008 2016 bl uuuu u00u1 u #d 024 7 $a10.2471/BLT.16.173377$2DOI 100 1 $aANDRADE, P. P. de 245 $aUse of transgenic Aedes aegypti in Brazil$brisk perception and assessment.$h[electronic resource] 260 $c2016 520 $aThe OX513A strain of Aedes aegypti, which was developed by the British company Oxitec, expresses a self-limiting transgene that prevents larvae from developing to adulthood. In April 2014, the Brazilian National Technical Commission on Biosafety completed a risk assessment of OX513A and concluded that the strain did not present new biological risks to humans or the environment and could be released in Brazil. At that point, Brazil became the first country to approve the unconstrained release of a genetically modified mosquito. During the assessment, the commission produced a comprehensive list of ? and systematically analysed ? the perceived hazards. Such hazards included the potential survival to adulthood of immature stages carrying the transgene ? should the transgene fail to be expressed or be turned off by exposure to sufficient environmental tetracycline. Other perceived hazards included the potential allergenicity and/or toxicity of the proteins expressed by the gene, the potential for gene flow or increased transmission of human pathogens and the occupation of vacant breeding sites by other vector species. The Zika epidemic both elevated the perceived importance of Ae. aegypti as a vector ? among policy-makers and regulators as well as the general public ? and increased concerns over the release of males of the OX513A strain. We have therefore reassessed the potential hazards. We found that release of the transgenic mosquitoes would still be both safe and of great potential value in the control of diseases spread by Ae. aegypti, such as the chikungunya, dengue and Zika virus disease. 650 $aAedes aegypti 650 $aDengue 650 $aTransgenes 650 $aZika virus 650 $aDoença 650 $aMosquito 650 $aTetraciclina 653 $aAedes transgênico 653 $aChikungunya 653 $aMétodo de controle 653 $aMosquito geneticamente modificado 700 1 $aARAGAO, F. J. L. 700 1 $aCOLLI, W. 700 1 $aDELLAGOSTIN, O. A. 700 1 $aFINARDI-FILHO, F. 700 1 $aHIRATA, M. H. 700 1 $aLIRA-NETO, A. de C. 700 1 $aMELO, M. A. de 700 1 $aNEPOMUCENO, A. L. 700 1 $aNOBREGA, F. G. da 700 1 $aSOUSA, G. D. de 700 1 $aVALICENTE, F. H. 700 1 $aZANETTINI, M. H. B. 773 $tBulletin of the World Health Organization, Geneva$gv. 94, p. 766-771, Oct. 2016.
Download
Esconder MarcMostrar Marc Completo |
Registro original: |
Embrapa Recursos Genéticos e Biotecnologia (CENARGEN) |
|
Biblioteca |
ID |
Origem |
Tipo/Formato |
Classificação |
Cutter |
Registro |
Volume |
Status |
Fechar
|
Nenhum registro encontrado para a expressão de busca informada. |
|
|